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Reply
We appreciate the interest of the readers above in our study
analyzing the association of statins with mortality after infraingui-
nal bypass in patients with critical limb ischemia. Their insightful
comments point to a weakness inherent to all nonrandomized
studies—propensity score models or multivariable regression mod-
els can only control for measured confounders and not unmea-
sured confounders. Our study did not control for cholesterol
levels, because these values were not available from our source data
(the PREVENT III trial).
While we agree with the readers that there is a small body of
literature, primarily pertaining to general surgery, that has sug-
gested a potential benefit to hypercholesterolemia, this effect has
yet to be demonstrated in patients with peripheral arterial disease.
Nonetheless, our data do not allow us to refute the comments of
the readers above—it is possible that, in our study, some of the
mortality benefit that was attributed to the use of statins may have
been affected by concurrent hypercholesterolemia in the patient
group on statin therapy.
Andres Schanzer, MD
Division of Vascular and Endovascular Surgery
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Worcester, Mass
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Carotid artery stenting: a promising therapeutic
option for carotid artery stenosis or a bubble about
to burst?
A recent prospective randomized trial compared for the first
time the long-term results of carotid endarterectomy (CEA) with
carotid artery stenting (CAS) (median observation time: 64 12.1
months vs. 66  12.1 months, respectively).1 This study showed
that CEA is superior to CAS with respect to stroke (0 of 42 vs. 4 of
42, respectively),70% restenosis (0 of 29 vs. 6 of 32, respectively)
and re-intervention rates (0 of 29 vs. 5 of 32, respectively; for all
associations P  .05).1
Two issues may hamper the interpretation of the results of this
study:1 first, CAS was performed without the use of embolic
protecting devices (EPDs).1 Although the exact role of EPDs in
CAS has not yet been established, their use may offer considerable
advantages. For example, a large (n  1,483 patients), multi-
center (n 26 hospitals), randomized study comparing CAS with
vs. without EPDs demonstrated that, compared with non-use, the
use of EPDs during CAS was associated with lower ipsilateralstroke (4.1% vs. 1.7%, respectively; P  .007) and lower non-fatal
stroke and death rates (4.9% vs. 2.1%, respectively; P  .004).2
Opposing results were reported in a recent prospective random-
ized study comparing the incidence of embolic lesions during CAS
with vs. without EPDs;3 the use of EPDs during CAS did not
reduce the number of emboli (average number of embolic lesions:
6.1 vs. 6.2, respectively; P  .79).3 A possible explanation for this
lack of difference may be the small size of CAS procedures included
(n  36).3
A second drawback is the early recruitment period (August
1999 to April 2002).1 Since then, the technique of CAS has
evolved considerably; new, better-designed, and improved stent
models have been introduced and employed. Additionally, physi-
cians have gradually become more experienced; a study presenting
a detailed analysis of periprocedural complications of CAS demon-
strated the importance of an appropriate learning curve before
systematic use of CAS.4 Thus, it could be expected that a similar
study performed today might produce different results than the
ones reported.1
The role of CAS in the treatment of carotid artery stenosis is
still the subject of extensive debate. Current evidence suggests that
it may still be premature to attempt to draw definite conclusions.
Kosmas I. Paraskevas, MD, FASA
Department of Vascular Surgery
“Red Cross” Hospital
Athens, Greece
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Reply
Thank you for the opportunity to respond to the letter con-
cerning our article “Alert for increased long-term follow-up after
carotid artery stenting: Results of a prospective, randomized, single-
center trial of carotid artery stenting vs carotid endarterectomy.”
Carotid endarterectomy (CEA) or carotid artery stenting
(CAS) in symptomatic patients is performed to reduce the risk of
secondary stroke or stroke-related death. Therefore, the main
focus of this article was the evaluation of restenosis, secondary
stroke rate, and death in a long-term follow-up of a prospective,
randomized study of CEA vs CAS.
We understand the concern that embolic protection devices
(EPD) might reduce peri-interventional stroke rates after CAS.
However, the cited publication1 is not a randomized study but
rather a registry from multiple cardiology centers during 1998 to
2003. The use of embolic protection devices (EPD) increased over
